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Abst ract
Niemann-Pick disease type C is a rare hereditary disorder
caused by mutation-disrupted metabolism of cholesterol and
low-density lipoprotein (LDL). In most patients, symptoms
begin in childhood with severe clinical progression. We pre-
sent a patient with heterozygote mutations 3001A>G and
3019C>G with late onset of the disease and positive response
to treatment with miglustat. Behaviour and educational prob-
lems in childhood were probably related to the disease diag-
nosed later.
Key words: Niemann-Pick type C, heterozygote mutation,
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A case report of ‘variant’ biochemical phenotype of Niemann-Pick C disease 
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CASE REPORT/OPIS PRZYPADKU
St reszc zenie
Choroba Niemanna-Picka typu C jest rzadkim schorzeniem
dziedziczonym autosomalnie recesywnie, spowodowanym
zaburzeniem metabolizmu i transportu cholesterolu i LDL.
Zachorowanie w wiêkszoœci przypadków dotyczy okresu dzie-
ciêcego i ma ciê¿ki przebieg kliniczny. W artykule przedsta-
wiono przypadek pacjenta z potwierdzon¹ z³o¿on¹ mutacj¹
3001A>G i 3019C>G o póŸnym pocz¹tku wyst¹pienia
zaburzeñ neurologicznych i korzystn¹ odpowiedzi¹ na lecze-
nie miglustatem. Zaburzenia zachowania w wieku dzieciêcym
i trudnoœci w nauce s¹ najprawdopodobniej zwi¹zane przy-
czynowo z póŸniej zdiagnozowan¹ chorob¹.
S³owa kluczowe: choroba Niemanna-Picka typu C, mutacja
z³o¿ona, miglustat.
Introduction
Niemann-Pick disease type C (NPC) is a rare here-
ditary disease transmitted as an autosomal recessive 
trait. Its incidence in the European population is esti-
mated at 1 in 150 000 live births. More than 95% of
patients with NPC harbor mutations in the NPC1 gene
on chromosome 18q11. Others have mutations in the
NPC2 gene on chromosome 14q24.3. Accumulation of
non-esterified cholesterol, gangliosides and other gly-
colipids in lysosomes and endosomes is a biochemical
hallmark of the disease [1-4]. Neurons and visceral
organs (liver and spleen) are the main site of the lipid
accumulation. The diagnosis may be difficult in patients
with late onset (over 15 years of age) due to a low pre-
va lence and variable clinical syndromes. Psychiatric
symptoms, extrapyramidal syndromes and dementia
dominate in the clinical picture of the late-onset cases.
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A ‘variant form’ of the disease with low accumulation of
cholesterol in cultured fibroblasts is more common in
adult cases, while the ‘classical form’ dominates among
childhood and adolescence [3,5].   
Case report
The patient, a 21-year-old male, was admitted to 
the Department of Neurology due to progressive ataxia
recognized at the age of 18. In childhood, the patient
was suspected of suffering from temporal epilepsy 
but that diagnosis was not confirmed. Then, activities 
of lysosomal enzymes measured in leucocytes were in 
the normal range. He also expressed aggressive and 
antisocial behaviour at school. He completed seconda-
ry school education. Progressive intellectual decline has
been observed for the last three years (in annual Wechs -
ler’s test examinations scores of 80, 69 and 59, respec-
tively). Family history did not reveal any neurological
or psychiatric conditions.
During the first hospitalization in our department,
his neurological examination revealed lower limb ataxia
and speech ataxia. Decline in non-routine activities and
avoidance of interpersonal relations were also observed.
Psychological examination revealed mild cognitive impa-
irment measured by WAIS-R/PL test (IQ verbal score
was 68, non-verbal – 54; total – 59). Cube test and digit
symbols indicated visuospatial disability. The patient also
had impairment of abstract thinking and executive func-
tions, and misunderstanding of social situations. Gene-
rally, the cognitive deficit resembles mixed cortical and
subcortical pattern. The same test performed two years
later showed no deterioration.
During multiple admissions to the hospital, spinoce-
rebellar ataxias (SCA) 1, 2, 3, 6, 7 and 8, Friedreich dise-
ase, and vitamin E deficiency were excluded. Two years
later, progression of the cerebellar and psychoorganic
syndrome was noticed. At that time, the patient also suf-
fered from two complex partial seizures that progressed
to secondarily generalized seizures. Seizures were treated
effectively with sodium valproate (600 mg/daily) for 
5 months and then the treatment was discontinued possi-
bly due to a lack of seizures.
Magnetic resonance imaging showed only mild cere-
bellar atrophy. Abdomen ultrasonography revealed hepa-
tosplenomegaly. Lipidogram showed increased concen-
trations of total cholesterol (219 mg%) and triglycerides
(275 mg%). Diagnostic tests excluded the following dise-
ases: Huntington disease, Wilson disease, dentatorubral-
pallidoluysian atrophy (DRPLA), spinocerebellar ataxia
type 17 (SCA 17), metachromatic leukodystrophy, 
gangliosidoses GM1 and GM2, and Niemann-Pick 
disease type B. Increased chitotriosidase activity in the
serum, tested three times (> 525 nmol/ml/h, control 
< 150 nmol/ml/h), combined with increased activity of
sphingomyelinase in leucocytes (Table 1) and mild accu-
mulation of free cholesterol in only a few of the cultured
fibroblasts, suggested a diagnosis of NPC. That diag -
nosis was confirmed by molecular analysis. Two muta-
tions in exon 20 of the NPC1 gene (c.3001A>G and
c.3019C>G) were found in the region coding for a cyste-
ine-rich loop. In healthy parents and the younger brother,
enzymatic tests and DNA test had not been performed.
Treatment with simvastatin (20 mg/daily), and eze-
timibe (10 mg/daily) was ineffective in terms of progres -
sive neurological and mental dysfunction [6]. The lat-
 ter treatment was discontinued after publication of
negative results in a clinical trial with ezetimibe perfor-
med in NPC patients. Finally, we recommended vita-
min E and a low-cholesterol diet.  
In February 2009, miglustat was introduced at
300 mg daily. Improvement of coordination movements,
gait, dysphagia, speech and normalization of mood
Enzyme Activity Units Mean control values
Arylsulfatase A (37°C) 136 nmol/mg protein/hour 105 ± 30
 α-Galactosidase 17 nmol/mg protein/hour 10 ± 2.5
β-Galactosidase 185 nmol/mg protein/hour 166 ± 99
Total β-glucosaminidase 905 nmol/mg protein/hour 665 ± 239
β-Glucosaminidase, % of the thermostable form 56 % 52 ± 8
α-Mannosidase 41 nmol/mg protein/hour 63 ± 35
Sphingomyelinase 279 nmol/mg protein/18 hours 70-108 
Table 1. Lysosomal enzyme activity in leucocytes
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disorders were observed. The rate of improvement fluc-
tuated from day to day. One-month suspension of the
treatment with miglustat brought about deterioration 
of cerebellar syndrome, loss of clinical flu ctuation, repe-
titive falls, and apathy.
The most recent neurological examination revealed
cerebellar syndrome with ataxic speech and gait, brisk
tendon reflexes without pyramidal signs, and for the first
time, mild periodic vertical oculomotor apraxia. The pa -
tient was cooperative, active and cheerful.
Discussion
Patients with late onset ataxia are often a diagnostic
challenge. The patient described here was eventually
diagnosed with NPC. NPC can develop at any age but
late onset forms with clinically predominant ataxia are
rather rare. Some clinical features can help in the dia-
gnostic process: learning problems, psychiatric disor-
ders (visual hallucinations, delusions and aggressive
behaviour), gaze palsy, epilepsy, history of liver disease
and splenomegaly, late onset ataxia and dystonia [5,7,8].
In our case, the patient lacked typical signs of NPC such
as major psychiatric disorders or epilepsy at onset of the
disease and, until the latest examination, there were no
signs of gaze palsy. On the other hand, he suffered from
learning problems, ataxia and hepatosplenomegaly. In
our opinion, NPC should be taken into consideration
in differential diagnosis in patients with late onset ata-
xia, especially with splenomegaly. Increased chitotriosi-
dase activity may suggest, as in our patient, that a gene-
tic test for NPC gene mutations is necessary [9,10]. To
date neuroimaging findings play only a supplementary
role in the diagnostic process [11,12].
Mutation c.3019C>G [P1007A] in the NPC1
gene identified in a heterozygous state in our patient was
described for the first time by Greer et al. in 1999. Sin-
ce then, it has been found to be one of the most frequ-
ent mutations in late onset and variant cases of NPC1
[13]. The second mutation found in our patient is
c.3001A>G [M1001V], a novel mutation. Both muta-
tions result in amino acid substitutions located in the
cysteine-rich luminal loop of the NPC1 protein, which
serves as a signal target for lysosomes. 
Treatment for NPC is currently under investigation,
with many substances being scanned for potential bene-
ficial results. Due to the dysfunction of cholesterol meta-
bolism, statins were tried as one of the first therapies,
but showed no benefit [14]. Significant but small
improvement slowing down the dynamics of progres-
sion was found in Npc1–/– mice after treatment with
tamoxifen and vitamin E [15]. Tamoxifen has multiple
metabolic effects, among others on ceramide glycosyla-
tion. It also reduces oxidative stress damage. The latter
is also obtained with vitamin E. Another substance
which was proven effective in the treatment of NPC
mice was allopregnanolone, which delayed the demyeli-
nation processes and prolonged survival [16,17], delay-
ed cholesterol accumulation, reduced autophagic/lyso-
somal dysfunction and inflammation processes, and also
enhanced myelination [18]. Another trial using anti-
inflammatory therapy was also proven beneficial in mice
[19]. Another substance tried was imatinib, a c-Ab-
specific inhibitor used in treatment of certain types of
leukemia, and was found to block cerebellar apoptosis
and improve neurological symptoms in a mouse model
of NPC [20,21]. Activation of pregnane X receptor
(PXR) and a liver X receptor agonist also slowed neu-
rodegeneration and increased the lifespan of NPC1 mice
[22,23]. Neural stem cells implanted in NPC1 mice
also showed benefit [24]. Trials of gene therapy in ani-
mals to inhibit cyclin-dependent kinase 5 reduced the
number of axonal spheroids, delayed the death of Pur-
kinje cells and significantly attenuated the hyperpho-
sphorylation of tau proteins [25]. These animal studies
show that improvement can be achieved using many dif-
ferent approaches at a metabolic level.
So far, only one randomized controlled study in
humans has been published showing effects of treatment
of NPC disease with miglustat [26]. Miglustat is an
iminosugar that reversibly inhibits glucosyl ceramide 
synthase, which catalyses the first step of glycosphingo-
lipid synthesis. Miglustat was originally approved for
treatment of another lysosomal storage disorder – Gau-
cher disease. In this trial, 29 patients aged 12 years or
older were randomized to receive either miglustat 200 mg
three times a day or standard treatment. The pri ma ry
endpoint of that study was horizontal saccadic eye move-
ment (HSEM) velocity, which corresponded with dise-
ase progression. At the observation after 12 months, mi -
glustat showed improvement or stabilization of HSEM.
That result suggested that ganglioside accumulation 
was partially responsible for the neurological symptoms
in NPC patients [27]. Another possible option to treat
NPC1 is ganaxolone, a GABA-A agonist and a deriva-
tive of pregnenolone, currently being tested in clinical
trials as an antiepileptic drug with clinical efficacy and
mild side effects [28].
Recent reports show that the role of NPC1 protein
is more complex than just the control of lipid metabo-
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lism. It may also regulate copper metabolism and vita-
min E status, suppress oxidative stress, and even parti-
cipate in Alzheimer disease pathology [29-32].
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